CLINICAL_TRIALS
trial_result
· 2025-07-10
Clinical Trial Update: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders [Phase 1]
Summary
A Phase I trial evaluating BAT4406F injection in patients with Neuromyelitis Optica Spectrum Disorders has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bio-Thera Solutions | Conditions: Neuromyelitis Optica Spectrum Disorders | Phase 1 | Status: COMPLETED